🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Robert Z. Orlowski We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/science/myelom…

Our research evaluating the accuracy and reliability of AI-powered chatbots in answering cancer-related questions in multiple languages, via EurekAlert!! eurekalert.org/news-releases/… Big thank you to @UniversityofSharjah Global Media Unit for getting this out to a broader audience.

Glad to see our recent study on patient-reported physical function predicting treatment benefit in multiple myeloma has been selected as “𝐒𝐭𝐮𝐝𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐃𝐚𝐲” and has been featured by OncoDaily – a leading global platform for oncology news. oncodaily.com/science/myelom…

Indeed! Very interesting results. Thanks for Sharing Robert Z. Orlowski

sharjah.ac.ae/en/Research/RI…

Could a common cholesterol medication help in cancer care? New research found statin use was linked to a 61% lower risk of cancer-related death in patients with CLL or SLL receiving targeted therapy. Read more: ow.ly/scYW50VGl6o #Leusmh #Lmsm Blood Advances UOS

تصدرت دراستنا المنشورة حديثا من جامعة الشارقة ومعهد برجيل للأورام وجامعة هارفارد في مجلة الدم التابعة للجمعية الأمريكية للأورام الأخبار العلمية حول العالم بما فيها جريدة التيليجراف البريطانية. ووجدت دراستنا أن بعض مرضى سرطان الدم الذين يتناولون أدوية الستاتين مع علاجهم تقل لديهم

Concurrent statin use with contemporary treatment regimens significantly improved survival outcomes in patients with treatment-naïve or relapsed/refractory CLL or SLL. #lymsm #leusm | Ahmad Abuhelwa hubs.li/Q03k849c0

Statin significantly improves overall survival and progression-free survival in patients with #CLL and #SLL treated with frontline ibrutinib, according to a study led by Ahmad Abuhelwa, of UOS, and published in Blood Advances. ➡️ buff.ly/bc1yn3s

“Statins could become an easy and cost-effective way to improve survival in patients with CLL.” Ahmad Abuhelwa discussed the potential survival benefits of statin use in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. جامعة الشـارقة bit.ly/4dhQIK3

Our pooled analysis of ibrutinib trials demonstrating statins to be strongly associated with improved survival outcomes in patients with CLL/SLL doi.org/10.1182/blooda…

Statin use and survival in SLL/CLL treated with ibrutinib: Pooled analysis of four randomized controlled trials | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Glad to share our new study—showing the predictive power of patient-reported physical function in MM. Patients with greater physical limitations gained the most survival benefit from daratumumab. What patients say about their health is predictive! doi.org/10.1111/ejh.14…

دراسة دولية بقيادة جامعة الشارقة تمنح الأمل لمرضى السرطان sharjah24.ae/ar/Articles/20…

Stop by our poster this morning at #ASCO25 to hear more about updates on OS analysis with CARTITUDE-4 in high risk sub groups. #mmsm

دراستنا العلمية من جامعة الشارقة ومعهد برجيل للأورام ومركز دانا فاربر للأورام - هارفارد - بوسطن ، وضحت بأن أدوية الكوليسترول (الستاتين) قد تحسن فرص البقاء على الحياة لدى مرضى اللوكيميا اللمفاوية المزمنة (CLL) أو اللمفوما اللمفاوية الصغيرة (SLL)، خاصة عند تلقيهم علاجات مثل

📢 “Patient voice holds real clinical power.” Ahmad Abuhelwa of جامعة الشـارقة talked with HemOnc Today about results showing patient-reported physical function had associations with outcomes for patients with #multiplemyeloma treated with daratumumab. bit.ly/4lFgYRk

Patient-reported outcomes on physical function may help predict which patients with #multiplemyeloma better respond to daratumumab. “I’m genuinely surprised how strongly the patient voice came through the data,” Ahmad Abuhelwa جامعة الشـارقة. bit.ly/4lFgYRk